« Potassium Iodide Pills |
| More Bad News in the UK: Novartis Horsham »
March 16, 2011
Pfizer Moves Antibacterials to Shanghai
So Pfizer has announced that their antibacterial research is moving to the Shanghai site. Is this the first example of a large/traditional therapeutic area moving to China? And if it is, should we care? After all, there are Swiss, German, British, and Japanese companies, among others, with multinational research sites. Some programs run at one facility, and some at another. When you add China to that list, though, something happens for a lot of people.
That's because the Chinese sites got their start as the inexpensive way to offshore work, for one thing. But Shanghai's not as cheap as it used to be - it's still less expensive than doing the work in the US or western Europe, but the cost advantage is eroding. Another factor is that you don't see companies expanding into new therapeutic areas these days, so much as moving the existing ones around. In that zero-sum game, expanding one site means contracting another.
Here's something to think about, though: does Pfizer's choice here represent a calculation about some future opportunity in China, should they be able to develop any drugs? Would the "discovered and developed in Shanghai" factor help with the regulatory authorities there?
+ TrackBacks (0) | Category: Business and Markets | Infectious Diseases
POST A COMMENT
- RELATED ENTRIES
- Gitcher SF5 Groups Right Here
- Changing A Broken Science System
- One and Done
- The Latest Protein-Protein Compounds
- Professor Fukuyama's Solvent Peaks
- Novartis Gets Out of RNAi
- Total Synthesis in Flow
- Sweet Reason Lands On Its Face